I agree about the near term re-rating.
CEO advised in a recent investor update that the prelim results for the first cohort of CDH17 CART patients will be released very soon (read early January?) - currently waiting on FDA approval.
this is the lowest dose level in the dose escalation but early signs of safety, efficacy and pharmokinetics should get a lot of market and big pharma interest. this is the first and only CDH17 cart therapy for gastric cancer currently being trialed globally. the FDA would likely assign breakthrough / regen medicine designation if the results are promising....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |